Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 4/20 | 0.51 |
| ▸ | LMNA | P02545 | 3/20 | 0.51 |
| ▸ | HTT | P42858 | 2/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
| ▸ | DGAT1 | O75907 | 5/20 | 0.48 |
| ▸ | KDM5B | Q9UGL1 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL441511 | 0.85 | EPHX2 (0.53) | HTTDGAT1 | |
| SCHEMBL440469 | 0.85 | EPHX2 (0.54) | DGAT1 | |
| SCHEMBL442251 | 0.85 | MEN1 (0.51) | LMNAHTTMEN1KMT2ADGAT1 | |
| SCHEMBL438045 | 0.84 | EPHX1 (0.54) | LMNAHTTALDH1A1MEN1KMT2A | |
| SCHEMBL439487 | 0.79 | DGAT1 (0.49) | ALDH1A1DGAT1KDM5B | |
| SCHEMBL442372 | 0.79 | DGAT1 (0.49) | ALDH1A1DGAT1KDM5B | |
| SCHEMBL440581 | 0.79 | DGAT1 (0.60) | ALDH1A1DGAT1KDM5B | |
| SCHEMBL441709 | 0.79 | DGAT1 (0.48) | DGAT1 | |
| SCHEMBL10280215 | 0.78 | DGAT1 (0.49) | ALDH1A1DGAT1KDM5B | |
| SCHEMBL438095 | 0.78 | DGAT1 (0.49) | ALDH1A1DGAT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120065196-A1 | AMIDE COMPOUNDS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-03-15 | — | — | US | disclosed |
| US-20120065196-A1 | AMIDE COMPOUNDS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-03-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120065196-A1 | AMIDE COMPOUNDS | DGAT2, DGAT1, DLAT | TSHR 2375/4885LMNA 4016/4885HTT 567/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.